Search

Displaying results 4951 - 4960 of 10000 in total
  1. Drug

    Glofitamab

    go.drugbank.com/drugs/DB16371
    ApprovedInvestigational

    ], [vincristine], [prednisone])[L45763] - despite this, as many as 40% of patients will experience relapsed or refractory disease. … In June 2023, the FDA approved the use of glofitamab for the treatment of patients with relapsed or refractory DLBCL not otherwise specified or large B-cell lymphoma (LBCL) arising from follicular lymphoma

  2. Drug

    Isepamicin

    go.drugbank.com/drugs/DB13540
    Experimental

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  3. Drug

    Talizumab

    go.drugbank.com/drugs/DB05797
    Experimental

    TNX-901 is a therapeutic monoclonal antibodies designed to address significant unmet medical needs in the areas of asthma, allergy, inflammation and other diseases affecting the human immune system.

  4. Drug

    Pentostatin

    go.drugbank.com/drugs/DB00552
    ApprovedInvestigational

    It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. … The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia.

  5. Drug

    Prednisolone sodium metazoate

    go.drugbank.com/drugs/DB05340
    Investigational

    Colal-Pred is being studied for use in ulcerative colitis. … ATL-2502(Colal-Pred) is an old drug (prednisolone metasulphobenzoate, a steroid) with a new delivery system that releases the medication only in the colon.

  6. Drug

    ATL1101

    go.drugbank.com/drugs/DB05023
    Experimental

    ATL1101 is being developed as a cream for the topical treatment of mild to moderate cases of psoriasis. … ATL1101 is a second-generation antisense drug designed to block the synthesis of the IGF-1 receptor, a protein involved in the regulation of cell overgrowth in psoriasis.

  7. Drug

    ALGRX 1207

    go.drugbank.com/drugs/DB06482
    Experimental

    ALGRX 1207 is a topical local anesthetic that acts by binding to the fast sodium channel. … ALGRX 1207 entered clinical trials for cutaneous neuropathic pain, such as chemotherapy-induced neuropathy, in 2006. It was being developed by Anesiva, but trials have halted.

  8. Drug

    DPI-221

    go.drugbank.com/drugs/DB06121
    Experimental

    DPI-221 is an investigational drug and a selective agonist for the δ-opioid receptor.

    Synonyms: BENZAMIDE, N,N-DIETHYL-4-((S)-((2S,5R)-4-((3-FLUOROPHENYL)METHYL)-2,5-DIMETHYL-1-PIPERAZINYL)PHENYLMETHYL)-, N,N-DIETHYL-4-((S)-((2S,5R)-4-((3-FLUOROPHENYL)METHYL)-2,5-DIMETHYL-1-PIPERAZINYL)PHENYLMETHYL)BENZAMIDE
  9. Drug

    CGC-11047

    go.drugbank.com/drugs/DB05722
    Investigational

    CGC-11047 is a polyamine analog designed to halt cell growth and induce apoptosis.

  10. Drug

    Anatibant

    go.drugbank.com/drugs/DB05038
    Experimental

    Anatibant is a selective, very potent, small-molecule Bradykinin B2 receptor antagonist. It is developed for the for the treatment of traumatic brain injury (TBI).